The clinical and biological significance of HER2 over-expression in breast ductal carcinoma in situ: a large study from a single institution
(2019)
Journal Article
© 2019, Cancer Research UK. Background: Previous studies have reported up to 50% of ductal carcinoma in situ (DCIS), is HER2 positive, but the frequency of HER2-positive invasive breast cancer (IBC) is lower. The aim of this study is to characterise... Read More about The clinical and biological significance of HER2 over-expression in breast ductal carcinoma in situ: a large study from a single institution.